vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v12i3.687vsp-336Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSОПЫТ ВЕДЕНИЯ ПАЦИЕНТА С ТЯЖЕЛЫМ ТЕЧЕНИЕМ ПСОРИАТИЧЕСКОГО АРТРИТАMANAGEMENT OF A PATIENT WITH SEVERE COURSE OF PSORIATIC ARTHRITISАлексееваЕ. И.AlexeevaE. I.

Alekseeva Ekaterina Iosifovna, PhD, professor, Head of Rheumatological Department of RAMS, Head of the Faculty of Pediatricsof I.M. Sechenov First Moscow State Medical University

Address: Lomonosovskij prospekt, 2, building 1,Moscow, Russian Federation, 119991, Tel.: (499) 134-02-97, e-mail: alekatya@yandex.ru

alekatya@ya.ruБзароваТ. М.BzarovaT. M.alekatya@ya.ruФетисоваА. Н.FetisovaA. N.alekatya@ya.ruВалиеваС. И.ValievaS. I.alekatya@ya.ruСлепцоваТ. В.SleptsovaT. V.alekatya@ya.ruИсаеваК. Б.IsaevaK. B.alekatya@ya.ruДенисоваР. В.DenisovaR. V.alekatya@ya.ruМитенкоЕ. В.MitenkoE. V.alekatya@ya.ruЧистяковаЕ. Г.ChistyakovaE.G.alekatya@ya.ruНаучный центр здоровья детей РАМН, Москва; Первый московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Centre of Children Health of RAMS, Moscow; I.M. Sechenov First Moscow State Medical University,Russian FederationНаучный центр здоровья детей РАМН, МоскваРоссияScientific Centre of Children Health of RAMS, MoscowRussian FederationНаучный центр здоровья детей РАМН, Москва,РоссияScientific Centre of Children Health of RAMS, MoscowRussian FederationНаучный центр здоровья детей РАМН, Москва; Первый московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Centre of Children Health of RAMS, Moscow; I.M. Sechenov First Moscow State Medical UniversityRussian Federation201314052013123Вопросы современной педиатрии9096Copyright © Алексеева Е.И., Бзарова Т.М., Фетисова А.Н., Валиева С.И., Слепцова Т.В., Исаева К.Б., Денисова Р.В., Митенко Е.В., Чистякова Е.Г., 20132013Алексеева Е.И., Бзарова Т.М., Фетисова А.Н., Валиева С.И., Слепцова Т.В., Исаева К.Б., Денисова Р.В., Митенко Е.В., Чистякова Е.Г.Alexeeva E.I., Bzarova T.M., Fetisova A.N., Valieva S.I., Sleptsova T.V., Isaeva K.B., Denisova R.V., Mitenko E.V., Chistyakova E.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/336

Представлен опыт ведения пациента с псориатическим артритом, характеризующимся тяжелым течением, наличием системных проявлений, высокими лабораторными показателями активности, полиартикулярным суставным синдромом, типичными изменениями кожи и ногтей, быстрой инвалидизацией пациента, низким уровнем качества жизни ребенка и его семьи. Продемонстрирована высокая эффективность биологической терапии этанерцептом. Через 3 мес лечения достигнута стадия неактивной болезни, через 9 мес — клинико-лабораторная ремиссия, причем со стороны не только суставного синдрома, но и экстраартикулярных и кожных проявлений и лабораторных показателей активности.

A history case of a patient with psoriatic arthritis, characterized by severe disease course, systemic symptoms, significantly increased laboratory markers, polyarticular syndrome, typical skin and nails changes, rapid development of patient’s disability and low quality of his and his family life is presented in this article. The authors showed high efficacy of treatment with biological agent — etanercept. In 3 months of treatment non-active stage of disease was achieved, in 9 months — clinical and laboratory remission, not only of the articular syndrome, but also of the extra-articular and dermatological manifestations and laboratory markers of the activity.

детипсориатический артритпсориазадалимумабэтанерцептchildrenpsoriatic arthritispsoriasisadalimumabetanerceptReferencesLandells I., MacCallum C., Khraishi M. The role of the dermatologist in identification and treatment of the early stages of psoriatic arthritis. Skin Therapy Lett. 2008; 13 (4): 4–7.Landells I., MacCallum C., Khraishi M. The role of the dermatologist in identification and treatment of the early stages of psoriatic arthritis. Skin Therapy Lett. 2008; 13 (4): 4–7.Cassidy J. T., Petty R. E., Laxer R. M. et al. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier. 2010. 794 p.Cassidy J. T., Petty R. E., Laxer R. M. et al. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier. 2010. 794 p.Bzarova T.M., Alekseeva E. I., Peterkova V. A. Voprosi sovremennoi pediatrii — Current Pediatrics. 2006; 5 (5): 13–18.Bzarova T.M., Alekseeva E. I., Peterkova V. A. Voprosi sovremennoi pediatrii — Current Pediatrics. 2006; 5 (5): 13–18.Alekseeva E. I., Bzarova T. M., Valieva S. I. Voprosi sovremennoi pediatrii — Current Pediatrics. 2012; 11 (4): 82–88.Alekseeva E. I., Bzarova T. M., Valieva S. I. Voprosi sovremennoi pediatrii — Current Pediatrics. 2012; 11 (4): 82–88.Alekseeva E. I., Lisitsin A. O., Karagulyan N. A. Voprosi sovremennoi pediatrii — Current Pediatrics. 2009; 08 (03): 88–94.Alekseeva E. I., Lisitsin A. O., Karagulyan N. A. Voprosi sovremennoi pediatrii — Current Pediatrics. 2009; 08 (03): 88–94.Lisitsin A. O., Alekseeva E. I., Bzarova T. M. Voprosi sovremennoi pediatrii — Current Pediatrics. 2008; 7 (5): 115–120.Lisitsin A. O., Alekseeva E. I., Bzarova T. M. Voprosi sovremennoi pediatrii — Current Pediatrics. 2008; 7 (5): 115–120.Romero-Mate A., Garcia-Donoso C., Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am. J. Clin. Dermatol. 2007; 8 (3): 143–155.Romero-Mate A., Garcia-Donoso C., Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am. J. Clin. Dermatol. 2007; 8 (3): 143–155.Mrowietz U., Barth J., Boehncke W. H., Rosenbach T., Wozel G. Therapy of psoriasis vulgaris and psoriatic arthritis with etanercept. J. Dtsch. Dermatol. Ges. 2005; 3 (6): 470–472.Mrowietz U., Barth J., Boehncke W. H., Rosenbach T., Wozel G. Therapy of psoriasis vulgaris and psoriatic arthritis with etanercept. J. Dtsch. Dermatol. Ges. 2005; 3 (6): 470–472.Bonafede M., Johnson B. H., Fox K. M., Watson C., Gandra S. R. Treatment patterns with etanercept or adalimumab for psoriatic diseases in a real-world setting. J. Dermatol. Treat. 2013. PMID: 23441722 [PubMed — as supplied by publisher].Bonafede M., Johnson B. H., Fox K. M., Watson C., Gandra S. R. Treatment patterns with etanercept or adalimumab for psoriatic diseases in a real-world setting. J. Dermatol. Treat. 2013. PMID: 23441722 [PubMed — as supplied by publisher].Alekseeva E. I., Valieva S. I., Denisova R.V. Voprosi sovremennoi pediatrii — Current Pediatrics. 2008; 7 (5): 51–56.Alekseeva E. I., Valieva S. I., Denisova R.V. Voprosi sovremennoi pediatrii — Current Pediatrics. 2008; 7 (5): 51–56.Yubo C., Xiaosheng L. Clinical trial of etanercept tapering in idiopathic arthritis during remission. Rheumatol. Int. doi: 10.1007/s00296-012-2642-7. 2013/Yubo C., Xiaosheng L. Clinical trial of etanercept tapering in idiopathic arthritis during remission. Rheumatol. Int. doi: 10.1007/s00296-012-2642-7. 2013/Denisova R. V., Alekseeva E. I., Al'bitskii V.Yu. Voprosi sovremennoi pediatrii — Current Pediatrics. 2009; 08 (03): 18–26.Denisova R. V., Alekseeva E. I., Al'bitskii V.Yu. Voprosi sovremennoi pediatrii — Current Pediatrics. 2009; 08 (03): 18–26.Gallyamova Yu. A. Lechashhij vrach — Practicing Doctor. 2008; 03.Gallyamova Yu. A. Lechashhij vrach — Practicing Doctor. 2008; 03.Beukelman T., Patkar N. M., Saag K. G., Tolleson-Rinehart S., Cron R. Q., DeWitt E. M., Ilowite N. T., Kimura Y., Laxer R. M., Lovell D. J., Martini A., Rabinovich C. E., Ruperto N. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. (Hoboken). 2011; 63 (4): 465–482.Beukelman T., Patkar N. M., Saag K. G., Tolleson-Rinehart S., Cron R. Q., DeWitt E. M., Ilowite N. T., Kimura Y., Laxer R. M., Lovell D. J., Martini A., Rabinovich C. E., Ruperto N. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. (Hoboken). 2011; 63 (4): 465–482.Baranov A. A., Alekseeva E. I., Bzarova T. M. Voprosi sovremennoi pediatrii — Current Pediatrics. 2013; 12 (1): 37–31.Baranov A. A., Alekseeva E. I., Bzarova T. M. Voprosi sovremennoi pediatrii — Current Pediatrics. 2013; 12 (1): 37–31.Petty R. E., Southwood T. R., Manners P., Baum J. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision. Edmonton. 2001. J. Rheumatol. 2004; 31 (2): 390–392.Petty R. E., Southwood T. R., Manners P., Baum J. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision. Edmonton. 2001. J. Rheumatol. 2004; 31 (2): 390–392.Hawrot A. C., Metry D. W., Theos A. J., Levy M. L. Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr. Dermatol. 2006; 23 (1): 67–71.Hawrot A. C., Metry D. W., Theos A. J., Levy M. L. Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr. Dermatol. 2006; 23 (1): 67–71.Alekseeva E. I., Alekseeva A. M., Valieva S. I. Voprosi sovremennoi pediatrii — Current Pediatrics. 2008; 7 (4): 30–44.Alekseeva E. I., Alekseeva A. M., Valieva S. I. Voprosi sovremennoi pediatrii — Current Pediatrics. 2008; 7 (4): 30–44.Kozlova A. L., Alekseeva E. I., Valieva S. I. Voprosi sovremennoi pediatrii — Current Pediatrics. 2009; 08 (02): 20–26.Kozlova A. L., Alekseeva E. I., Valieva S. I. Voprosi sovremennoi pediatrii — Current Pediatrics. 2009; 08 (02): 20–26.Romero-Mate A., Garcia-Donoso C., Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am. J. Clin. Dermatol. 2007; 8 (3): 143–155.Romero-Mate A., Garcia-Donoso C., Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am. J. Clin. Dermatol. 2007; 8 (3): 143–155.de Vries H. S., van Oijen M. G., Driessen R. J., de Jong E. M., Creemers M. C., Kievit W., de Jong D. J. Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Brit. J. Clin. Pharmacol. 2011; 71 (1): 7–19. Doi: 10.1111/j.1365- 2125.2010.03760.x.de Vries H. S., van Oijen M. G., Driessen R. J., de Jong E. M., Creemers M. C., Kievit W., de Jong D. J. Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Brit. J. Clin. Pharmacol. 2011; 71 (1): 7–19. Doi: 10.1111/j.1365- 2125.2010.03760.x.De Sanctis S., Marcovecchio M. L., Gaspari St. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis. J. Rheumatol. 2013; 40: 6.De Sanctis S., Marcovecchio M. L., Gaspari St. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis. J. Rheumatol. 2013; 40: 6.Trachana M., Pratsidou-Gerts P., Badouraki M. Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2–10-year etanercept exposure. Clin. Rheumatol. Doi: 10.1007/S10067-013-2261-Z. 2013.Trachana M., Pratsidou-Gerts P., Badouraki M. Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2–10-year etanercept exposure. Clin. Rheumatol. Doi: 10.1007/S10067-013-2261-Z. 2013.Bracaglia C., Buonuomo P. S., Tozzi Al. E. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. J. Rheumatol. 2012; 39: 6.Bracaglia C., Buonuomo P. S., Tozzi Al. E. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. J. Rheumatol. 2012; 39: 6.

The authors declare that there are no conflicts of interest present.